David H Cribbs

List of Publications by Year
in descending order

118 papers	13,232 citations	46918 47 h-index	24915 109 g-index
119 all docs	119 docs citations	119 times ranked	16997 citing authors

#	Article	IF	Citations
1	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
2	A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nature Methods, 2005, 2, 599-605.	9.0	1,007
3	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
4	AÎ² Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome. Neuron, 2004, 43, 321-332.	3.8	746
5	Structureâ€Activity Analyses of Î²â€Amyloid Peptides: Contributions of the Î²25â€“35 Region to Aggregation and Neurotoxicity. Journal of Neurochemistry, 1995, 64, 253-265.	2.1	641
6	Gene expression changes in the course of normal brain aging are sexually dimorphic. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15605-15610.	3.3	520
7	Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. Journal of Neuroinflammation, 2012, 9, 179.	3.1	423
8	Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal Î²-Catenin Pathway Function in an Alzheimerâ€™s Disease Model. Journal of Immunology, 2011, 187, 6539-6549.	0.4	359
9	Microfluidic Multicompartment Device for Neuroscience Researchâ€. Langmuir, 2003, 19, 1551-1556.	1.6	278
10	Reduction of Soluble AÎ² and Tau, but Not Soluble AÎ² Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles. Journal of Biological Chemistry, 2006, 281, 39413-39423.	1.6	262
11	Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1653-1661.	1.5	261
12	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
13	Patterned cell culture inside microfluidic devices. Lab on A Chip, 2005, 5, 102.	3.1	255
14	Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. International Immunology, 2003, 15, 505-514.	1.8	254
15	Localization and Cell Association of C1q in Alzheimer's Disease Brain. Experimental Neurology, 1996, 138, 22-32.	2.0	211
16	Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. Journal of Neuroinflammation, 2008, 5, 13.	3.1	196
17	Prototype Alzheimerâ€™s Disease Vaccine Using the Immunodominant B Cell Epitope from Î²-Amyloid and Promiscuous T Cell Epitope Pan HLA DR-Binding Peptide. Journal of Immunology, 2005, 174, 1580-1586.	0.4	192
18	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166

#	Article	IF	Citations
19	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
20	Activation of Caspase-8 in the Alzheimer's Disease Brain. Neurobiology of Disease, 2001, 8, 1006-1016.	2.1	162
21	Correlation between Caspase Activation and Neurofibrillary Tangle Formation in Alzheimerâ€™s Disease. American Journal of Pathology, 2001, 158, 189-198.	1.9	156
22	Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimerâ€™s Disease. ENeuro, 2017, 4, ENEURO.0149-16.2017.	0.9	149
23	Aspirin-Triggered Lipoxin A4 Stimulates Alternative Activation of Microglia and Reduces Alzheimer Diseaseâ€“Like Pathology in Mice. American Journal of Pathology, 2013, 182, 1780-1789.	1.9	139
24	Aspartate residue 7 in amyloid Î²-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis. Nature Medicine, 1997, 3, 077-079.	15.2	134
25	Blocking AÎ²₄₂Accumulation Delays the Onset and Progression of Tau Pathology via the C Terminus of Heat Shock Protein70-Interacting Protein: A Mechanistic Link between AÎ² and Tau Pathology. Journal of Neuroscience, 2008, 28, 12163-12175.	1.7	123
26	Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1961-1972.	1.5	114
27	Phagocytosis of Amyloid-Î² and Inflammation: Two Faces of Innate Immunity in Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 457-463.	1.2	105
28	Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine â€” A Novel Immunotherapeutic Strategy. PLoS ONE, 2008, 3, e2124.	1.1	100
29	Loss of Muscarinic M1 Receptor Exacerbates Alzheimer's Diseaseâ€“Like Pathology and Cognitive Decline. American Journal of Pathology, 2011, 179, 980-991.	1.9	100
30	Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. Journal of Neuroscience, 2013, 33, 4923-4934.	1.7	100
31	Fibril Formation and Neurotoxicity by a Herpes Simplex Virus Glycoprotein B Fragment with Homology to the Alzheimer's AÎ² Peptide. Biochemistry, 2000, 39, 5988-5994.	1.2	94
32	Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric AÎ² Species in Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 2007, 27, 12721-12731.	1.7	94
33	Anti-AÎ²1â€“11 Antibody Binds to Different Î²-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers. Journal of Biological Chemistry, 2007, 282, 22376-22386.	1.6	90
34	Complement Association with Neurons and Î²-Amyloid Deposition in the Brains of Aged Individuals with Down Syndrome. Neurobiology of Disease, 2001, 8, 252-265.	2.1	89
35	A Monoclonal Antibody to Amyloid Precursor Protein Induces Neuronal Apoptosis. Journal of Neurochemistry, 2002, 74, 2331-2342.	2.1	86
36	All-D-Enantiomers of Î²-Amyloid Exhibit Similar Biological Properties to All-L-Î²-Amyloids. Journal of Biological Chemistry, 1997, 272, 7431-7436.	1.6	82

#	Article	IF	Citations
37	Fas and Fas Ligand are associated with neuritic degeneration in the AD brain and participate in Î²-amyloid-induced neuronal death. Neurobiology of Disease, 2003, 12, 182-193.	2.1	82
38	Reductions in Amyloid-Î²-Derived Neuroinflammation, with Minocycline, Restore Cognition but do not Significantly Affect Tau Hyperphosphorylation. Journal of Alzheimer's Disease, 2010, 21, 527-542.	1.2	79
39	Frontal Cortex Neuropathology in Dementia Pugilistica. Journal of Neurotrauma, 2012, 29, 1054-1070.	1.7	77
40	Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-AÎ² antibody response with Alum to Quil A adjuvant switch. Vaccine, 2006, 24, 2275-2282.	1.7	76
41	Restoration of Lipoxin A4 Signaling Reduces Alzheimer's Disease-Like Pathology in the 3xTg-AD Mouse Model. Journal of Alzheimer's Disease, 2014, 43, 893-903.	1.2	76
42	Amyloid-Î² Peptide Binds to Cytochrome C Oxidase Subunit 1. PLoS ONE, 2012, 7, e42344.	1.1	73
43	Caspase-Mediated Degeneration in Alzheimer's Disease. American Journal of Pathology, 2004, 165, 353-355.	1.9	61
44	A murine model of inflammation-induced cerebral microbleeds. Journal of Neuroinflammation, 2016, 13, 218.	3.1	61
45	Generation and characterization of the humoral immune response to DNA immunization with a chimericÎ²-amyloid-interleukin-4 minigene. European Journal of Immunology, 2003, 33, 3232-3241.	1.6	59
46	Importance of IgG2c isotype in the immune response to Î²-amyloid in amyloid precursor protein/transgenic mice. Neuroscience Letters, 2003, 338, 5-8.	1.0	57
47	Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Annals of the New York Academy of Sciences, 2010, 1207, 58-70.	1.8	56
48	Chronic Kidney Disease Increases Cerebral Microbleeds in Mouse and Man. Translational Stroke Research, 2020, 11, 122-134.	2.3	51
49	Experimental Investigation of Antibody-Mediated Clearance Mechanisms of Amyloid-Î² in CNS of Tg-SwDI Transgenic Mice. Journal of Neuroscience, 2007, 27, 13376-13383.	1.7	48
50	Comparative Analysis of H&E and Prussian Blue Staining in a Mouse Model of Cerebral Microbleeds. Journal of Histochemistry and Cytochemistry, 2014, 62, 767-773.	1.3	47
51	Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human Î±-synuclein: Feasibility study. Neuroscience Letters, 2014, 560, 86-91.	1.0	44
52	Brain Penetrating Bifunctional Erythropoietinâ€“Transferrin Receptor Antibody Fusion Protein for Alzheimerâ€™s Disease. Molecular Pharmaceutics, 2018, 15, 4963-4973.	2.3	42
53	Epitopeâ€based DNA vaccine for Alzheimer's disease: Translational study in macaques. Alzheimer's and Dementia, 2014, 10, 284-295.	0.4	41
54	Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Molecular Neurodegeneration, 2017, 12, 33.	4.4	40

#	Article	IF	Citations
55	Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. Journal of Cellular Biochemistry, 2006, 98, 1037-1043.	1.2	38
56	Alzheimerâ€™s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and AÎ² pathological molecules. Scientific Reports, 2016, 6, 28912.	1.6	37
57	Therapeutic Modulation of Cerebral Microhemorrhage in a Mouse Model of Cerebral Amyloid Angiopathy. Stroke, 2011, 42, 3300-3303.	1.0	36
58	Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention. CNS and Neurological Disorders - Drug Targets, 2010, 9, 207-216.	0.8	36
59	Novel approaches for immunotherapeutic intervention in Alzheimer's disease. Neurochemistry International, 2006, 49, 113-126.	1.9	35
60	Mannan-Abeta28conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. Journal of Neuroinflammation, 2008, 5, 42.	3.1	35
61	The Bradykinin B1 Receptor Regulates AÎ² Deposition and Neuroinflammation in Tg-SwDI Mice. American Journal of Pathology, 2013, 182, 1740-1749.	1.9	35
62	Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to Alzheimerâ€™ Î² amyloid peptide. , 2002, , 719-720.		35
63	Mixed Cerebrovascular Disease and the Future of Stroke Prevention. Translational Stroke Research, 2012, 3, 39-51.	2.3	34
64	Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. Journal of Neuroinflammation, 2005, 2, 28.	3.1	33
65	DNA epitope vaccine containing complement component C3d enhances anti-amyloid-Î² antibody production and polarizes the immune response towards a Th2 phenotype. Journal of Neuroimmunology, 2008, 205, 57-63.	1.1	33
66	Î² amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: Usage of a novel blood brain barrier endothelial cell model system. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 153-165.	1.4	31
67	Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cellular Immunology, 2011, 270, 188-197.	1.4	30
68	Bapineuzumab Alters AÎ² Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy. PLoS ONE, 2013, 8, e59735.	1.1	30
69	Aging exacerbates development of cerebral microbleeds in a mouse model. Journal of Neuroinflammation, 2018, 15, 69.	3.1	30
70	Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites. Journal of Immunology, 2007, 178, 566-573.	0.4	28
71	Refinement of a DNA based Alzheimer disease epitope vaccine in rabbits. Human Vaccines and Immunotherapeutics, 2013, 9, 1002-1010.	1.4	28
72	Biologic TNF-Î± inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy. Journal of Neuroinflammation, 2021, 18, 312.	3.1	28

#	Article	IF	Citations
73	AÎ²-Immunotherapy for Alzheimer's Disease Using Mannanâ€“Amyloid-Beta Peptide Immunoconjugates. DNA and Cell Biology, 2006, 25, 571-580.	0.9	27
74	External force-assisted cell positioning inside microfluidic devices. Biomedical Microdevices, 2007, 9, 15-23.	1.4	26
75	Amyloid-Î² peptide binds to microtubule-associated protein 1B (MAP1B). Neurochemistry International, 2008, 52, 1030-1036.	1.9	26
76	Immunostimulant Adjuvant Patch Enhances Humoral and Cellular Immune Responses to DNA Immunization. DNA and Cell Biology, 2008, 27, 19-24.	0.9	26
77	The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. , 2014, 10, 271-283.		23
78	Immunization with Amyloid-Î² Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model. Journal of Neuroscience, 2009, 29, 6132-6141.	1.7	22
79	Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid Î² peptide. Molecular Immunology, 2010, 48, 59-72.	1.0	22
80	Delivery of a DNA Vaccine for Alzheimerâ€™s Disease by Electroporation versus Gene Gun Generates Potent and Similar Immune Responses. Neurodegenerative Diseases, 2012, 10, 261-264.	0.8	22
81	Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease epitope vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 1248-1255.	1.4	22
82	Î²-Amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome. Neuroscience Letters, 2002, 330, 99-103.	1.0	21
83	Brain endothelial cell enzymes cleave platelet-retained amyloid precursor protein. Translational Research, 1998, 132, 341-350.	2.4	20
84	Experimental hypertension increases spontaneous intracerebral hemorrhages in a mouse model of cerebral amyloidosis. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 399-404.	2.4	20
85	MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine, 2017, 35, 2015-2024.	1.7	20
86	Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. Neurobiology of Disease, 2020, 139, 104823.	2.1	20
87	Testing a MultiTEP-based combination vaccine to reduce AÎ² and tau pathology in Tau22/5xFAD bigenic mice. Alzheimer's Research and Therapy, 2019, 11, 107.	3.0	19
88	Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human Î±-synuclein: prelude for IND enabling studies. Npj Vaccines, 2022, 7, 1.	2.9	19
89	Blood brain barrier endothelial cells express candidate amyloid precursor protein-cleaving secretases. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 153-162.	1.4	18
90	Identification of N-Terminally Truncated Pyroglutamate Amyloid-Î² in Cholesterol-Enriched Diet-Fed Rabbit and AD Brain. Journal of Alzheimer's Disease, 2014, 39, 441-455.	1.2	18

#	Article	IF	Citations
91	A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice. Scientific Reports, 2019, 9, 15455.	1.6	18
92	Voltage modulation of a gated ion channel admittance in platinum-supported lipid bilayers. Biosensors and Bioelectronics, 1992, 7, 11-20.	5.3	17
93	Immunization with fibrillar AÎ²1â€“42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain AÎ². Vaccine, 2006, 24, 2824-2834.	1.7	16
94	Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiology of Disease, 2010, 39, 301-310.	2.1	16
95	Genetic Ablation of Hematopoietic Cell Kinase Accelerates Alzheimerâ€™s Diseaseâ€“Like Neuropathology in Tg2576 Mice. Molecular Neurobiology, 2020, 57, 2447-2460.	1.9	15
96	Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors. Clinical and Experimental Metastasis, 2003, 20, 489-498.	1.7	13
97	Relapsing polychondritis with features of dementia with Lewy bodies. Acta Neuropathologica, 2006, 112, 217-225.	3.9	13
98	Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of Î²-Amyloid in an Animal Model of Alzheimerâ€™s Disease. Molecular Therapy, 2017, 25, 153-164.	3.7	13
99	Hematologic safety of chronic brainâ€penetrating erythropoietin dosing in APP/PS1 mice. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 627-636.	1.8	13
100	Anti-11[E]-pyroglutamate-modified amyloid Î² antibodies cross-react with other pathological AÎ² species: Relevance for immunotherapy. Journal of Neuroimmunology, 2010, 229, 248-255.	1.1	12
101	Effects of Dabigatran in Mouse Models of Aging and Cerebral Amyloid Angiopathy. Frontiers in Neurology, 2019, 10, 966.	1.1	12
102	Manifestations of Alzheimerâ€™s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	1.6	12
103	Modulation of a gated ion channel admittance in lipid bilayer membranes. Biosensors and Bioelectronics, 1991, 6, 425-430.	5.3	11
104	Mimotopes of conformational epitopes in fibrillar Î²-amyloid. Journal of Neuroimmunology, 2004, 156, 10-20.	1.1	10
105	Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]. CNS and Neurological Disorders - Drug Targets, 2009, 8, 1-6.	0.8	10
106	BTX AgilePulse^{TM} System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine. Current Gene Therapy, 2014, 14, 190-199.	0.9	9
107	Low Concentrations of Anti-AÎ² Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology. Human Gene Therapy, 2010, 21, 1569-1576.	1.4	8
108	Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. Journal of Neuroimmunology, 2014, 268, 50-57.	1.1	8

#	Article	IF	Citations
109	MultiTEP platformâ€“based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiology of Aging, 2017, 59, 156-170.	1.5	8
110	Effects of phosphodiesterase 3A modulation on murine cerebral microhemorrhages. Journal of Neuroinflammation, 2017, 14, 114.	3.1	8
111	Editorial [Hot Topic: Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part II (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]. CNS and Neurological Disorders - Drug Targets, 2009, 8, 82-87.	0.8	7
112	Cerebral Blood Flow in Chronic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105702.	0.7	6
113	Insights Into the Mechanisms of Brain Endothelial Erythrophagocytosis. Frontiers in Cell and Developmental Biology, 2021, 9, 672009.	1.8	5
114	The Î²-Amyloid Model of Alzheimerâ€™s Disease. , 1997, , 73-90.		5
115	Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological Î±-Synuclein. International Journal of Molecular Sciences, 2022, 23, 6080.	1.8	5
116	Spectroscopic and deep learning-based approaches to identify and quantify cerebral microhemorrhages. Scientific Reports, 2021, 11, 10725.	1.6	1
117	Abstract W MP94: Acute Inflammation Expands Cerebral Microbleeds in a Mouse Model of Cerebral Amyloid Angiopathy. Stroke, 2014, 45, .	1.0	0
118	Using Digital Pathology to Identify and Quantify Cerebral Microhemorrhages. , 2021, , .		0